DK2897939T3 - Benzoimidazolcarboxylsyreamidderivater til behandling af metaboliske eller kardiovaskulære sygdomme - Google Patents

Benzoimidazolcarboxylsyreamidderivater til behandling af metaboliske eller kardiovaskulære sygdomme Download PDF

Info

Publication number
DK2897939T3
DK2897939T3 DK13763087.7T DK13763087T DK2897939T3 DK 2897939 T3 DK2897939 T3 DK 2897939T3 DK 13763087 T DK13763087 T DK 13763087T DK 2897939 T3 DK2897939 T3 DK 2897939T3
Authority
DK
Denmark
Prior art keywords
carbonyl
amino
ylmethyl
thiophen
benzoimidazole
Prior art date
Application number
DK13763087.7T
Other languages
English (en)
Inventor
Stephanie Hachtel
Paulus Wohlfart
Marco Müller
Elisabeth Defossa
Katharina Mertsch
jian-hui Weng
Farid Abdul-Latif
William Jerome Bock
Armin Walser
Robert A Binnie
John Weston
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK2897939T3 publication Critical patent/DK2897939T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (15)

1. Forbindelse
med formel I, hvor R', R", R'" uafhængigt af hinanden er H, halogen, CF3, OCF3, 0-(C1-C3) -alkyl; R1 er a) (C4-C7) -alkyl ; b) (C5-C7) -cycloalkyl, der er usubstitueret eller monosubstitueret med (C1-C2) -alkyl eller CF3; c) methylencyclohexyl; d) phenyl, der er usubstitueret eller monosubstitueret med methyl eller Cl; R2 er a) en 5-leddet heteroaryl, der indeholder 1 eller 2 identiske eller forskellige ringheteroatomer udvalgt blandt N, 0 og S, hvor den 5-leddede heteroaryl er usubstitueret eller monosubstitueret med Cl eller (C1-C4)-alkyl; b) phenyl; c) (C5-C6)-cycloalkyl; eller d) tetrahydrofuranyl; R3 er H eller (C1-C2) -alkyl; og R4 er a) (C3-C5)-alkyl, der eventuelt kan være substitueret med 1-3 F eller S-(C1-C4) -alkyl, b) (C0-C1)-alkylen-(C3-C7)-cycloalkyl, hvor cycloalkyl er usubstitueret eller mono- eller disubstitueret med methyl; c) (C0-C2) -alkylenphenyl, hvor phenyl er usubstitueret eller mono- eller disubstitueret med F, Cl, (C1-C4) -alkyl eller CF3; eller d) thienyl; eller R3 og R4 sammen med carbonatomet, hvortil de er bundet, danner en 5- til 7-leddet cycloalkylring, der er usubstitueret eller monosubstitueret med (C1-C4)-alkyl; R5 er H, (C1-C4) -alkyl eller OH; R6 er H eller (C1-C4)-alkyl; n er 0, 1 eller 2; og Z er CO2-R7, OR8, C (O) NR9R10, S (O) 2NRnR12,
·>: hvor v er 0 eller 2; R7 er H eller (C1-C4) -alkyl; R8 er H eller (C1-C4) -alkyl; R9 er H, (Ci-C4)-alkyl eller ethylen-O- (C1-C4) -alkyl; og R10 er a) H; b) (Ci-Ce) -alkyl, der er usubstitueret eller monosubstitueret med CF3; c) (C1-C2) -alkyl, der er substitueret med CN eller CO2R19,· hvor R19 er H eller (C1-C6)-alkyl; d) (C2-C4)-alkyl, der er monosubstitueret med en substituent udvalgt fra gruppen, der består af S-methyl, SO2NR20R21, O-R22 og NR23R24; hvor R20 er H; R21 er H; R22 er H, (C1-C3) -alkyl, methylencyclopropyl, methylenphenyl eller methylen-2-tetrahydrofuran; R23 er H eller (C1-C2)-alkyl; R24 er (C1-C2) -alkyl eller S02-methyl; e) (C3-C5)-cycloalkyl, der er usubstitueret eller monosubstitueret med phenyl; f) (C0-C2)-alkylenheterocycloalkyl, hvor heterocylcoalkyl er 5- eller 6-leddet og indeholder 1 eller 2 O-atomer i ikke-tilstødende positioner, og hvor heterocycloalkyl er usubstitueret eller geminalt disubstitueret med en spirocyclopentylring eller en spirocyclohexylring; g) (C2-C5)-alkylenheterocycloalkyl, hvor heterocycloalkyl er en 5-, 6- eller 7-leddet ring, der indeholder mindst ét N-atom, er bundet via N-atomet og yderligere kan indeholde ét heteroatom udvalgt fra gruppen, der består af 0, S(0)x eller NR25, i en position, der ikke støder op til N-atomet, hvormed ringen er bundet til alkylen, og hvor et hvilket som helst carbonatom i heterocycloalkyl er usubstitueret eller substitueret med 1 eller 2 substituenter udvalgt fra gruppen, der består af (C1-C3)alkyl eller methylenphenyl; hvor x er 2 ; R25 er H, (C1-C2) -alkyl, methylenphenyl eller phenyl, der er usubstitueret eller substitueret med 1 eller 2 substituenter udvalgt fra gruppen, der består af F, Cl og 0- (C1-C4)-alkyl; h) (C0-C3)-alkylenheterocycloalkyl, hvor heterocycloalkyl er en 5- eller 6-leddet ring, der indeholder mindst ét N-atom, ikke er bundet via N-atomet og yderligere kan indeholdet ét O-atom i en position, der ikke støder op til N-atomet, og hvor N-atomet er usubstitueret eller substitueret med en substituent udvalgt fra gruppen, der består af: i) (C1-C4)-alkyl, der er usubstitueret eller monosubstitueret med 0 (C1-C4)-alkyl; ii) methylencyclohexyl; iii) (C0-C2)-alkylenphenyl, hvor phenyl er usubstitueret eller substitueret med 1 eller 2 substituenter udvalgt fra gruppen, der består af F og 0(C1-C4)-alkyl; iv) (C0-C1) -alkylenpyridyl; v) pyrimidinyl; i) 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl; j) 9-methyl-9-aza-bicyclo[3.3.1]non-3-yl; k) methylen-4-(octahydroquinolizinyl) ; l) (Co-C2)-alkylenphenyl, hvor phenyl er usubstitueret eller monosubstitueret med substituenter udvalgt fra gruppen, der består af F, O (C1-C4) -alkyl, N ( (C1-C4)-alkyl) 2, 4-morpholinyl og methylen-(4-methylpiperidin)-1-yl eller disubstitueret på tilstødende positioner med gruppen -0(CH2)0-; m) (C1-C2) -alkylenheteroaryl, hvor heteroarylringen er en 5- eller 6-leddet ring, der indeholder 1, 2, 3 eller 4 heteroatomer udvalgt blandt 0, S eller N; og hvor heteroarylringen er usubstitueret eller monosubstitueret med oxo (=0); eller R9 og R10 sammen med N-atomet, der bærer dem, er a) en 4-, 5- eller 6-leddet heterocylcoalkylring, der kun indeholder N-atomet, hvortil Rs og R10 er bundet, der er usubstitueret eller monosubstitueret med en substituent udvalgt fra gruppen, der består af: i) (C0-C1) -alkylen-OR26, hvor R26 er H, (C1-C3) -alkyl eller methylenphenyl ; ii) CO2R27, hvor R27 er H eller (C1-C6) -alkyl; ii) NR28R29, hvor R28 er (C1-C2) -alkyl, og R29 er (C1-C2) -alkyl, methylenphenyl eller ethylen-N((C1-C4)-alkyl)2; iii) 1-piperidinyl, der er usubstitueret eller monosubstitueret med methyl; iv) 1-piperazinyl, der er usubstitueret eller monosubstitueret med methyl; v) 4-morpholinyl; vi) 1-azepanyl; vii) 2- (2,3-dihydro-lH-isoindolyl); b) en 6- eller 7-leddet heterocycloalkylring, der indeholder N-atomet, hvortil R9 og R10 er bundet, og ét yderligere heteroatom udvalgt blandt 0, S eller NR30 i en position, der ikke støder op til N-atomet, hvortil R9 og R10 er bundet, hvor carbonatomerne i heterocycloalkylringen er usubstitueret eller mono- eller disubstitueret med methyl, og hvor R30 er i) H; ii) (C1-C4) -alkyl; iii) (C5-C6) -cycloalkyl; iv) phenyl, der er usubstitueret eller monosubstitueret med F, CF3 eller O- (C1-C4) -alkyl; v) methylenphenyl, der er usubstitueret eller mono- eller disubstitueret med F eller Cl eller disubstitueret på tilstødende positioner med gruppen -0(CH2)0-; vi) pyridyl; c) en 2,5-diaza-bicyclo[2.2.1]heptylring, der er usubstitueret eller substitueret på det andet N-atom i 5-position med en substituent udvalgt fra gruppen, der består af (C1-C4)-alkyl, methylencyclopentyl, phenyl, der er usubstitueret eller monosubstitueret med F, methylenphenyl, hvor phenyl er usubstitueret eller monosubstitueret med 0- (C1-C4) -alkyl eller cf3; R11 er H; R12 er (C1-C4) -alkyl; R13 er H; R14 er CF3 eller methylen-O- (C1-C4) -alkyl; R15 er cyclopropyl eller phenyl; R16 er H eller (C1-C4) -alkyl; R17 er H eller (C1-C4) -alkyl; og R18 er (C1-C4) -alkyl; i en hvilken som helst af dens stereoisomere former eller en blanding af stereoisomere former i et hvilket som helst forhold eller et fysiologisk acceptabelt salt deraf eller et fysiologisk acceptabelt solvat af en hvilken som helst af disse.
2. Forbindelse med formel I ifølge krav 1, hvor R' , R", R"' er H; R1 er a) iso-butyl, sec-butyl, 1-ethylpropyl, 2-methylbutyl, 1,3-dimethylbutyl, l-isopropyl-2-methylpropyl; b) cyclopentyl, 2-methylcyclopentyl, cyclohexyl, 2- methylcyclohexyl, 2-(trifluormethyl)-cyclohexyl, 2- ethylcyclohexyl, cycloheptyl; c) methylencyclohexyl; d) phenyl, 2-chlorphenyl, 4-tolyl; R2 er a) 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 4-thiazolyl, 5-thiazoloyl, 1-pyrazolyl; 5-isoxazolyl, 5-methylthien-2-yl, 5-chlorthien-2-yl; b) phenyl; c) (C5-Cs)-cycloalkyl; eller d) 2-tetrahydrofuranyl ; R3 er H eller methyl; og R4 er a) (C3-C5)-alkyl, der eventuelt kan være substitueret med 1-3 F eller S-methyl, b) methylen-(C4-C6)-cycloalkyl; eller R3 og R4 sammen med carbonatomet, hvortil de er bundet, danner en 5- til 7-leddet cycloalkylring; R5 er H, methyl eller OH; R5 er H eller methyl; n er 0, 1 eller 2; og Z er CO2-R7, OR8, C (O) NR9R10, S (O) 2NR11R12,
hvor v er 0 eller 2; R7 er H; R8 er H eller (C1-C4)-alkyl; R9 er H, CH3; og R10 er a) H; b) (Ci-Cs) -alkyl, der er usubstitueret eller monosubstitueret med CF3; c) (C1-C2)-alkyl, der er substitueret med CN eller CO2R19; hvor R19 er H; d) (C2-C4) -alkyl, der er monosubstitueret med en substituent udvalgt fra gruppen, der består af S-CH3, SO2NR20R21, O-R22 og NR23R24; hvor R20 er H; R21 er H; R22 er H, (C1-C3)-alkyl, methylencyclopropyl, methylenphenyl eller methylen-2-tetrahydrofuran; R23 er H eller (C1-C2) -alkyl; R24 er (C1-C2) -alkyl eller SO2CH3; e) cyclobutyl, cyclopentyl eller 2-phenylcyclopropyl; f) (C0-C2)-alkylenheterocycloalkyl, hvor heterocycloalkyl er udvalgt fra gruppen, der består af 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl og 1,4-dioxan-2-yl; g) (C2-C5)-alkylenheterocycloalkyl, hvor heterocycloalkyl er udvalgt fra gruppen, der består af 1-pyrrolidinyl, 1- piperidinyl, 1-azepanyl, 4-morpholinyl 1,1-dioxothiomorpholin-4-yl og 1-piperazinyl; hvor heterocycloalkyl er usubstitueret eller substitueret med 1 eller 2 substituenter udvalgt fra gruppen, der består af (C1-C2)-alkyl eller methylenphenyl; h) (C0-C3) -alkylenheterocycloalkyl, hvor heterocycloalkyl er udvalgt fra gruppen, der består af 3-pyrrolidinyl, 2- piperidinyl, 3-piperidinyl, 4-piperidinyl og 2-morpholinyl og hvor heterocycloalkyl er substitueret med en substituent udvalgt fra gruppen, der består af i) (C1-C4)-alkyl; ii) methylencyclohexyl; iii) (C0-C2) -alkylenphenyl; iv) (C0-C1) -alkylenpyridyl; v) pyrimidinyl; i) 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl; j) 9-methyl-9-aza-bicyclo[3.3.1]non-3-yl; k) methylen-4-(octahydroquinolizinyl); l) (Co-C2) -alkylenphenyl, hvor phenyl er usubstitueret eller monosubstitueret med substituenter udvalgt fra gruppen, der består af F, 0-CH3, N (013)2; m) (C1-C2)-alkylenheteroaryl, hvor heteroarylringen er udvalgt fra gruppen, der består af 2-thienyl, 2-furanyl, 2-thiazolyl, 2-oxazolyl, 5-tetrazolyl og 5-oxo-4,5-dihydro-lH- [1,2,4]triazol-3-yl; eller R9 og R10 sammen med N-atomet, der bærer dem, er a) azetidinyl substitueret med CO2H; b) pyrrolidinyl, der er usubstitueret eller monosubstitueret med en substituent udvalgt fra gruppen, der består af i) OH; ii) methylen-0CH3; iii) methylen-O-methylenphenyl; iv) CO2H; v) NR28R29, hvor R28 er (C1-C2) -alkyl, og R29 er (C1-C2) -alkyl; vi) 1-piperazinyl, der er usubstitueret eller monosubstitueret med methyl; c) piperidinyl, der er monosubstitueret med en substituent udvalgt fra gruppen, der består af i) 0- (C1-C3) alkyl; ii) methylen-0-CH3; iii) NR28R29, hvor R23 er (C1-C2)-alkyl, og R29 er methylenphenyl eller ethylen-N (CH3) 2; iv) 1-piperidinyl, der er monosubstitueret med methyl; v) 1-piperazinyl, der er usubstitueret eller monosubstitueret med methyl; vi) 4-morpholinyl; vii) 1-azepanyl; viii) 2-(2,3-dihydro-lH-isoindolyl); d) 4-morpholinyl, der er disubstitueret med methyl; e) 4-thiomorpholinyl; f) piperazinyl, der er monosubstitueret med en substituent udvalgt fra gruppen, der består af: i) (C1-C4) -alkyl; ii) (Cs-Ce) -cycloalkyl; iii) phenyl, der er usubstitueret eller monosubstitueret med F, CF3 eller OCH3; iv) methylenphenyl, der er usubstitueret eller disubstitueret på tilstødende positioner med gruppen -0((¾) 0-; v) pyridyl; g) azepanyl, der er substitueret med methylenphenyl, der er usubstitueret eller mono- eller disubstitueret med F eller Cl; c) en 2,5-diaza-bicyclo[2.2.1]heptylring, der er substitueret på det andet N-atom i 5-position med en substituent udvalgt fra gruppen, der består af (C1-C4) -alkyl, methylencyclopentyl, phenyl, der er monosubstitueret med F, methylenphenyl, hvor phenyl er usubstitueret eller monosubstitueret med OCH3 eller CF3; R11 er H; R12 er CHS; R13 er H; R14 er CF3 eller methylen-OCH3; R15 er cyclopryopyl eller phenyl; R16 er H eller CH3; R17 er H eller CH3; og R18 er CH3; i en hvilken som helst af dens stereoisomere former eller en blanding af stereoisomere former i et hvilket som helst forhold eller et fysiologisk acceptabelt salt deraf eller et fysiologisk acceptabelt solvat af en hvilken som helst af disse.
3. Forbindelse med formel I ifølge krav 1 eller 2, hvor R' , R", R"' er H; R1 er 1-ethylpropyl; R2 er 3-thienyl; R3 er H; R4 er 2-methylpropyl; n er 0, 1, 2; og Z er C (0) NR9R10.
4. Forbindelse med formel I ifølge krav 1 eller 2, hvor R' , R", R"' er H; R1 er 1-ethylpropyl eller 2-methylcyclohexyl; R2 er 3-thienyl; R3 er H eller (C1-C2)-alkyl; og R4 er a) (C3-C5)-alkyl, der eventuelt kan være substitueret med 1-3 F eller S-(C1-C4) -alkyl, b) (C0-C1)-alkylen-(C3-C7)-cycloalkyl, hvor cycloalkyl er usubstitueret eller mono- eller disubstitueret med methyl; eller R3 og R4 sammen med carbonatomet, hvortil de er bundet, danner en 5- til 7-leddet cycloalkylring, der er usubstitueret eller monosubstitueret med (C1-C4)-alkyl; n er 0; og Z er CO2-H.
5. Forbindelse med formel I ifølge krav 1 eller 2, hvor R' , R", R"' er H; R1 er 1-ethylpropyl eller 2-methylcyclohexyl; R2 er 3-thienyl; R3 er H eller (C1-C2)-alkyl; og R4 er a) (C3-C5)-alkyl, der eventuelt kan være substitueret med 1-3 F eller S-(C1-C4) -alkyl, b) (C0-C1)-alkylen-(C3-C7)-cycloalkyl, hvor cycloalkyl er usubstitueret eller mono- eller disubstitueret med methyl; eller R3 og R4 sammen med carbonatomet, hvortil de er bundet, danner en 5- til 7-leddet cycloalkylring, der er usubstitueret eller monosubstitueret med (C1-C4)-alkyl; R5 er H, (C1-C4) -alkyl eller OH; R6 er H eller (C1-C4)-alkyl; n er 1; og Z er CO2-H.
6. Forbindelse med formel I ifølge krav 1 eller 2, hvor R', R", R'" er H; R1 er 1-ethylpropyl eller 2-methylcyclohexyl; R2 er 3-thienyl; R3 er H eller (C1-C2)-alkyl ; og R4 er a) (C3-C5)-alkyl, der eventuelt kan være substitueret med 1-3 F eller S-(C1-C4) -alkyl, b) (C0-C1)-alkylen-(C3-C7)-cycloalkyl, hvor cycloalkyl er usubstitueret eller mono- eller disubstitueret med methyl; eller R3 og R4 sammen med carbonatomet, hvortil de er bundet, danner en 5- til 7-leddet cycloalkylring, der er usubstitueret eller monosubstitueret med (C1-C4)-alkyl; R5 er H, (C1-C4) -alkyl eller OH; R5 er H eller (C1-C4)-alkyl; n er 2 ; og Z er CO2-H.
7. Forbindelse med formel I ifølge krav 1 eller 2, hvor R', R", R'" er H; R1 er 1-ethylpropyl; R2 er 3-thienyl; R3 er H eller (C1-C2)-alkyl; og R4 er a) (C3-C5)-alkyl, der eventuelt kan være substitueret med 1-3 F eller S-(C1-C4) -alkyl, b) (C0-C1)-alkylen-(C3-C7)-cycloalkyl, hvor cycloalkyl er usubstitueret eller mono- eller disubstitueret med methyl; eller R3 og R4 sammen med carbonatomet, hvortil de er bundet, danner en 5- til 7-leddet cycloalkylring, der er usubstitueret eller monosubstitueret med (C1-C4)-alkyl; R5 er H, (C1-C4) -alkyl eller OH; R5 er H eller (C1-C4)-alkyl; n er 1 eller 2; og Z er OR8, S (0) 2NR11R12, CN,
> hvor v er O eller 2; R8 er H; R11 er H; R12 er CH3; og R13 er H.
8. Forbindelse med formel I ifølge krav 1 eller 2, hvor R' , R", R"' er H; R1 er 1-ethylpropyl; R2 er 3-thienyl; R3 er H; R4 er 2-methylpropyl; n er 0; og Z er C (0) NR9R10; hvor R9 er H eller methyl; og R10 er: c) (C1-C2)-alkyl, der er substitueret med CN; d) (C2-C4)-alkyl, der er monosubstitueret med en substituent udvalgt blandt NR23R24; hvor R23 er H; R24 er (C1-C2)-alkyl eller S02-methyl; m) (Ci-C2)-alkylenheteroaryl, hvor heteroarylringen er en 5-eller 6-leddet ring, der indeholder 1, 2, 3 eller 4 heteroatomer udvalgt blandt 0, S eller N; og hvor heteroarylringen er usubstitueret eller monosubstitueret med oxo (=0); eller R9 og R10 sammen med N-atomet, der bærer dem, er a) en 4-, 5- eller 6-leddet heterocylcoalkylring, der kun indeholder N-atomet, hvortil R9 og R10 er bundet, der er usubstitueret eller monosubstitueret med en substituent udvalgt fra gruppen, der består af i) (Co-Ci)-alkylen-OR26, hvor R26 er H; ii) CO2R27, hvor R27 er H.
9. Forbindelse med formel I ifølge krav 1 eller 2, der er udvalgt fra gruppen, der består af 1 1-{ [1- (1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-cycloheptancarboxylsyre 6 1-{[1-(-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol- 5-carbonyl]-amino}-cyclopentancarboxylsyre
3-Cyclopentyl-2-{[1-(1-ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 12 2-{[1-(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-2,4-dimethylpentansyre 15 (S)-3-Cyclohexyl-2-{[1-(2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 16 (S)—2 —{ [1-(2-Methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-hexansyre 18 (S)—2—{ [1— (1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH- benzoimidazol-5-carbonyl]-amino}-hexansyre 21 (S)-3-Cyclopropyl-2-{[1-(1-ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 22 (S) -3-Cyclobutyl-2-{[1-(1-ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 2 3 (S) -3-Cyclobutyl-2- {[1-((1R,2R) -2-methylcyclohexyl) - 2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 24 l-{ [1- (1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH- benzoimidazol-5-carbonyl]-amino}-cyclohexancarboxylsyre 25 2-{[1-(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-2-methylpentansyre 26 2-{ [1- (1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH- benzoimidazol-5-carbonyl]-amino}-5,5,5-trifluorpentansyre 27 5,5,5-Trifluor-2-{[l-((lR,2R) -2-methylcyclohexyl ) - 2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-pentansyre 29 3-(4,4-Dimethylcyclohexyl)-2-{[1-(1-ethylpropyl)-2- thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 33 3-(4,4-Dimethylcyclohexyl)-2-{[1-((IR,2R)-2-methy1cyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 34 1-{ [1- (1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino} - 4- methyleyelohexancarboxylsyre
4-Methyl-1-{[1—((1R,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}- eyelohexancarboxylsyre 36 2-{ [1- (1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-3-(4-methylcyclohexyl) -propionsyre 38 1—{[1—((IR,2R)-2-Methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-eyelohexancarboxylsyre
3-Cycloheptyl-2-{[1-(1-ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre
3-Cycloheptyl-2-{[1-((IR,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre
3-Cyclohexyl-3-{[1-(1-ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 45 3-{[1-(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-heptansyre
4-Cyclohexyl-3-{[1-(1-ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-smørsyre 47 3-{[1- (1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-5,5-dimethylhexansyre 48 (R)—3—{[1—(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-5-methylhexansyre
4-Cyclohexyl-3-{[1-((1R,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethy1-lH-benzoimidazol-5-carbonyl]-amino}-smørsyre
4-Cyclohexyl-3-{[1-((IS,2S)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-smørsyre 53 (3R,4S)-4-Methyl-3-{[1—((1R,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}- hexansyre 54 (3R,4S)-3-{[l-(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-4-methylhexansyre 55 3-{[1-((1R,2R)-2-Methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-hexansyre 56 3—{[1—((1R,2R)-2-Methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-heptansyre
3-Cyclohexyl-3-{[1-((IR,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 58 3-{ [ 1- (1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH- benzoimidazol-5-carbonyl]-amino}-2,2-dimethylheptansyre
4-Ethyl-3-{[1-(1-ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-hexansyre 60 (S)-4-Cyclopentyl-3-{[1-(1-ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-smørsyre 61 (S)-4-Cyclopentyl-3-{[1-((IR,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazo1-5-carbonyl]-amino}-smørsyre 62 3-{[1-(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-2,2,5-trimethylhexansyre 63 3-{ [ 1-(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-2,2-dimethylhexansyre 64 (1-{ [1- (1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH- benzoimidazol-5-carbonyl]-amino}-cyclohexyl)-eddikesyre 66 (1—{[1—((IR,2R)-2-Methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-cyclohexyl)-eddikesyre 67 (2R,3S)-3-{[1-(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-2-hydroxy-5-methylhexansyre 68 (2S,3S)-3- { [1- (1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-2-hydroxy-5-methylhexansyre 70 (R)-6-Methyl-4-{[1-((1R,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-heptansyre 71 (4R,5S)-4-{[1-(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-5-methylheptansyre 72 (4R,5S)-5-Methyl-4-{[1-((IR,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-heptansyre 73 (3R,4S)-5-Cyclohexyl-4-{[1-(1-ethylpropyl)-2-thiophen-2- ylmethyl-lH-benzoimidazol-5-carbonyl]-amino} - 3-hydroxypentansyre 74 (3R,4S)-5-Cyclohexyl-3-hydroxy-4-{[l-((lR,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-pentansyre 75 (3S,4S)-4-{[l - (1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-3-hydroxy-6-methylheptansyre 76 (3R,4S)-4-{[l-(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-3-hydroxy-6-methylheptansyre 77 (3R, 4S)-3-Hydroxy-6-methyl-4-{[1-((IR,2R)-2-methy1cyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-heptansyre 78 (3S, 4S)-3-Hydroxy-6-methyl-4-{[1-((IR,2R)-2-methy1cyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazo1-5-carbonyl]-amino}-heptansyre 79 (3 S,4S)-5-Cyclohexyl-4-{[1-(1-ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino} - 3- hydroxypentansyre 91 (S)-2-{ [1-((IR, 2R)-2-Methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-pentansyre 92 (2 S,3S)-3-Methyl-2-{[1-((IR,2R)-2-methy1cyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-pentansyre 94 (S)—2—{ [1—(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-pentansyre 95 (S)—3—{ [1— (1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-5-methylhexansyre 101 (S)-5-Methyl-3-{[ 1-(2-methylcyclohexyl)-2-thiophen-2- ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-hexansyre 107 (S)—3—{ [1—(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH- benzoimidazol-5-carbonyl]-amino}-5-methylhexansyre 114 (S) -2-{ [1-(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH- benzoimidazol-5-carbonyl]-amino}-4-methylpentansyre 121 (S)-2-{[1-(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH- benzoimidazol-5-carbonyl]-amino}-3-methylpentansyre 123 (S)—2 — { [1—(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH- benzoimidazol-5-carbonyl]-amino}-4-methylsulfanyIsmørsyre 125 (S)-3-Cyclohexyl-2-{[1-(1-ethylpropyl)-2-thiophen-2- ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 130 (S)—2—{ [1—(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH- benzoimidazol-5-carbonyl]-amino}-5-methylhexansyre 139 (S)-4-Methyl-2-{[1-(2-methylcyclohexyl)-2-thiophen-3- ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-pentansyre 146 (S)-4-Methyl-2-{[1-(2-methylcyclohexyl)-2-thiophen-2- ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-pentansyre 153 (2S,3R)-2-{[l-(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH- benzoimidazol-5-carbonyl]-amino}-3-methylpentansyre 155 3-{[1-(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH- benzoimidazol-5-carbonyl]-amino}-hexansyre 161 (R)—3—{[1- (1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH- benzoimidazol-5-carbonyl]-amino}-4-methylpentansyre 162 (R)—4—{ [1—(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH- benzoimidazol-5-carbonyl]-amino}-5-methylhexansyre 163 (R)—4—{ [1—(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH- benzoimidazol-5-carbonyl]-amino}-6-methylheptansyre 412 (S)-4-Methyl-2-{[1-((IR,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-pentansyre 413 (S)-4-Methyl-2-{[1-((IS,2S)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-pentansyre 414 (S)-4-Methyl-2-{[1-((IR,2S)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino]-pentansyre 415 (S)-4-Methyl-2-{[1-((IS,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino]-pentansyre 420 (S) -2-{ [1-(2-Methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-hexansyre 421 (S) -2-{ [1-(2-Methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-hexansyre 422 (S)-2-{[1-(2-Methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-hexansyre 423 (S)-2-{[1-(2-Methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-hexansyre 424 (S)-3-Cyclohexyl-2-{[1-(2-methylcyclohexyl)-2-thiophen-2- ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 425 (S)-3-Cyclohexyl-2-{[1-(2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 426 (S)-3-Cyclohexyl-2-{[1-(2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 427 (S)-3-Cyclohexyl-2-{[1-(2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 436 (S) — 5 —Methyl — 3—{ [1-(2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-hexansyre 437 (S) -5 —Methyl-3—{[1-(2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-hexansyre 438 (S)-5-Methyl-3-{[1-(2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-hexansyre 439 (S)—5—Methyl—3—{[1-(2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-hexansyre 440 (R)-2-{[1-(1-Ethylpropyl)-2-thiophen-2-ylmethyl-1H-benzoimidazol-5-carbonyl]-amino}-2,4-dimethylpentansyre 441 (S) -2-{ [1-(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-2,4-dimethylpentansyre 442 3-Cyclopentyl-2-{[1-((IR,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 443 3-Cyclopentyl-2-{[1— ((IR,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 448 (S)-3-Cycloheptyl-2-{[1-(1-ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 449 (R)-3-Cycloheptyl-2-{[1-(1-ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 450 3-Cycloheptyl-2-{[1-((IR,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 451 3-Cycloheptyl-2-{[1-((IR,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}- propionsyre 452 (S)—3—{ [1—(1-Ethylpropyl)-2-thiophen-2-ylmethyl-1H-benzoimidazol-5-carbonyl]-amino}-heptansyre 453 (R)-3-{[1-(1-Ethylpropyl)-2-thiophen-2-ylmethyl-1H- benzoimidazol-5-carbonyl]-amino}-heptansyre 454 (S)-4-Cyclohexyl-3-{[1-(1-ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-smørsyre 455 (R)-4-Cyclohexyl-3-{[1-(1-ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-smørsyre 456 4-Cyclohexyl-3-{[1-((IR,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-smørsyre 457 4-Cyclohexyl-3-{[1-((IR,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-smørsyre 458 3-{[1-((IR,2R)-2-Methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-hexansyre 459 3-{[l-((lR,2R)-2-Methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-hexansyre 460 3—{[1—((1R,2R)-2-Methy1cyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-heptansyre 461 3-{[l-((lR,2R)-2-Methy1cyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-heptansyre 462 3-Cyclohexyl-3-{[1-((IR,2R)-2-methylcyclohexyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 4 63 3-Cyclohexyl-3-{ [1-((IR, 2R)-2-methylcyclohexyl)-2- thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-propionsyre 464 (R)—3—{ [1—(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-2,2,5-trimethylhexansyre 465 (S)—3—{[1-(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-2,2,5-trimethylhexansyre 466 (R)—3—{ [1—(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-2,2-dimethylhexansyre 467 (S)—3—{ [1—(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-2,2-dimethylhexansyre 468 (S)—3—{ [1—(1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH-benzoimidazol-5-carbonyl]-amino}-2,2-dimethylheptansyre 469 (R)—3—{ [1— (1-Ethylpropyl)-2-thiophen-2-ylmethyl-lH- benzoimidazol-5-carbonyl]-amino}-2,2-dimethylheptansyre; et fysiologisk acceptabelt salt deraf eller et fysiologisk acceptabelt solvat deraf.
10. Farmaceutisk sammensætning, der omfatter mindst én forbindelse med formel I ifølge et hvilket som helst af kravene 1 til 9 eller et fysiologisk acceptabelt solvat af en hvilken som helst af disse, til anvendelse som et farmaceutikum.
11. Forbindelse med formel I ifølge et hvilket som helst af kravene 1 til 9 eller et fysiologisk acceptabelt salt deraf eller et fysiologisk acceptabelt solvat af en hvilken som helst af disse til anvendelse som et farmaceutikum.
12. Forbindelse med formel I ifølge et hvilket som helst af kravene 1 til 9 eller et fysiologisk acceptabelt salt deraf eller et fysiologisk acceptabelt solvat af en hvilken som helst af disse til anvendelse til forebyggelse og behandling af kardiovaskulære sygdomme, herunder koronar hjertesygdom, apopleksi, hjerteinsufficiens, systolisk hjerteinsufficiens, diastolisk hjerteinsufficiens, diabetisk hjerteinsufficiens, hjerteinsufficiens med bevaret ejektionsfraktion, kardiomyopati, myokardieinfarkt, venstre ventrikulær dysfunktion, venstre ventrikulær dysfunktion efter myokardieinfarkt, hjertehypertrofi, myokardiel remodellering, myokardiel remodellering efter infarkt eller efter hjerteoperation og hjerteklapsygdomme.
13. Forbindelse med formel I ifølge et hvilket som helst af kravene 1 til 9 eller et fysiologisk acceptabelt salt deraf eller et fysiologisk acceptabelt solvat af en hvilken som helst af disse til anvendelse til forebyggelse og behandling af metabolisk syndrom, insulinresistens, diabetes melittus, diabetiske senkomplikationer, diabetiske makro- og mikrovaskulopatier, diabetisk nefropati, diabetisk retinopati, diabetisk neuropatier og kardiel autonom neuropati.
14. Forbindelse med formel I ifølge et hvilket som helst af kravene 1 til 9 eller et fysiologisk acceptabelt salt deraf eller et fysiologisk acceptabelt solvat af en hvilken som helst af disse til anvendelse til forebyggelse og behandling af sygdomme med forstyrret kropsvæskehomeostase ved CNS-afhængige og -uafhængige effekter, akut og kronisk nyresvigt, hypertension, pulmonal hypertension, portal hypertension og systolisk hypertension.
15. Forbindelse med formel I ifølge et hvilket som helst af kravene 1 til 9 eller et fysiologisk acceptabelt salt deraf eller et fysiologisk acceptabelt solvat af en hvilken som helst af disse til anvendelse til forebyggelse og behandling af forøget vaskulær permeabilitet og ikke-fungerende blodkar, vaskulær hypertrofi, vaskulær remodellering, vaskulær stivhed, aterosklerose, perifer arteriel okklusiv sygdom (PAOD), restenose, trombose, vaskulære permeabilitetsforstyrrelser, iskæmi, reperfusionsskade, iskæmi og/eller reperfusionsskade af hjerte, nyre og retina.
DK13763087.7T 2012-09-21 2013-09-19 Benzoimidazolcarboxylsyreamidderivater til behandling af metaboliske eller kardiovaskulære sygdomme DK2897939T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306142 2012-09-21
PCT/EP2013/069432 WO2014044738A1 (en) 2012-09-21 2013-09-19 Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators

Publications (1)

Publication Number Publication Date
DK2897939T3 true DK2897939T3 (da) 2017-05-08

Family

ID=47010450

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13763087.7T DK2897939T3 (da) 2012-09-21 2013-09-19 Benzoimidazolcarboxylsyreamidderivater til behandling af metaboliske eller kardiovaskulære sygdomme

Country Status (22)

Country Link
US (1) US9156796B2 (da)
EP (1) EP2897939B1 (da)
JP (1) JP6186438B2 (da)
KR (1) KR20150058284A (da)
CN (1) CN104640846A (da)
AU (1) AU2013320323B2 (da)
BR (1) BR112015005972A2 (da)
CA (1) CA2885272A1 (da)
CY (1) CY1118973T1 (da)
DK (1) DK2897939T3 (da)
ES (1) ES2623528T3 (da)
HR (1) HRP20170628T1 (da)
HU (1) HUE031733T2 (da)
IL (1) IL237212A (da)
LT (1) LT2897939T (da)
MX (1) MX2015003653A (da)
PL (1) PL2897939T3 (da)
PT (1) PT2897939T (da)
RU (1) RU2015114772A (da)
SG (1) SG11201501051UA (da)
SI (1) SI2897939T1 (da)
WO (1) WO2014044738A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1143120A (ja) * 1997-07-28 1999-02-16 Ishikawajima Harima Heavy Ind Co Ltd 容器の後処理装置
EA031804B1 (ru) 2014-02-03 2019-02-28 Вайтаи Фармасьютиклз, Инк. Дигидропирролопиридиновые ингибиторы ror-гамма
JP6592008B2 (ja) * 2014-04-23 2019-10-16 エックス−アールエックス， インコーポレイテッド オートタキシンの置換ｎ−（２−アミノ）−２−オキソエチルベンズアミド阻害剤およびそれらの調製、ならびにｌｐａ依存性またはｌｐａ媒介性疾患の処置における使用
WO2015188073A1 (en) * 2014-06-06 2015-12-10 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
GB201415569D0 (en) * 2014-09-03 2014-10-15 C4X Discovery Ltd Therapeutic Compounds
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2016176473A1 (en) * 2015-04-28 2016-11-03 Sanford-Burnham Medical Researc Institute Apelin receptor agonists and methods of use thereof
HUE050317T2 (hu) * 2015-05-20 2020-11-30 Amgen Inc APJ receptor triazol agonistái
ES2739526T3 (es) * 2015-06-03 2020-01-31 Bristol Myers Squibb Co Agonistas de APJ de 4-hidroxi-3-(heteroaril)piridin-2-ona para su uso en el tratamiento de trastornos cardiovaculares
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
CN108368087B (zh) * 2015-10-14 2022-04-12 百时美施贵宝公司 作为apj激动剂的2，4-二羟基-烟酰胺
EP3377482B1 (en) 2015-11-20 2021-05-12 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
US10626096B2 (en) 2015-11-24 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Azole derivatives as apelin receptor agonist
US11390616B2 (en) * 2015-12-04 2022-07-19 Bristol-Myers Squibb Company Apelin receptor agonists and methods of use
RU2021133849A (ru) * 2015-12-09 2022-03-21 Рисерч Трайэнгл Инститьют Улучшенные агонисты апелинового рецептора (apj) и их использование
JP6948322B2 (ja) * 2015-12-16 2021-10-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ａｐｊ受容体のａｐｊアゴニストとしてのヘテロアリールヒドロキシピリミジノン
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
GB201601703D0 (en) 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
CN107531679B (zh) * 2016-03-18 2021-07-02 江苏恒瑞医药股份有限公司 芳香酰胺类衍生物、其制备方法及其在医药上的应用
EP3228630A1 (en) 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
MA46540A (fr) 2016-10-12 2019-08-21 Res Triangle Inst Agonistes du récepteur de l'apéline (apj) hétérocyclique et leurs utilisations
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
TW201906816A (zh) * 2017-07-06 2019-02-16 大陸商江蘇恆瑞醫藥股份有限公司 吲哚甲醯胺類衍生物、其製備方法及其在醫藥上的應用
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
AR112461A1 (es) 2017-07-24 2019-10-30 Vitae Pharmaceuticals Inc PROCESOS PARA LA PRODUCCIÓN DE SALES Y FORMAS CRISTALINAS DE INHIBIDORES DE RORg
US11345705B2 (en) 2017-08-09 2022-05-31 Sanford Burnham Prebys Medical Discovery Institute Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists
EP3704122B1 (en) 2017-11-03 2021-09-01 Amgen Inc. Fused triazole agonists of the apj receptor
JP2021512151A (ja) 2018-01-23 2021-05-13 ネクストキュア インコーポレイテッド Ｂ７−ｈ４抗体およびその使用方法
EP3759095A1 (en) 2018-03-01 2021-01-06 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
PT3806855T (pt) * 2018-06-15 2023-05-03 Pfizer Agonistas dos receptores de glp-1 e suas utilizações
CN113490668A (zh) 2018-10-05 2021-10-08 安娜普尔纳生物股份有限公司 用于治疗与apj受体活性有关的疾病的化合物和组合物
KR20230169977A (ko) * 2021-03-10 2023-12-18 빈시어 바이오사이언시스, 인크. Usp30 억제제 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1060166A1 (de) * 1998-02-03 2000-12-20 Boehringer Ingelheim Pharma KG 5-gliedrige benzokondensierte heterocyclen als antithrombotika
US7294457B2 (en) 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
AU2002347022A1 (en) * 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
SE0301699D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1903052A3 (en) * 2006-07-28 2008-04-02 Faust Pharmaceuticals SA APJ receptor ligands and uses thereof
WO2008153701A1 (en) 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity

Also Published As

Publication number Publication date
CY1118973T1 (el) 2018-01-10
PL2897939T3 (pl) 2017-08-31
IL237212A0 (en) 2015-04-30
HUE031733T2 (en) 2017-07-28
RU2015114772A (ru) 2016-11-10
MX2015003653A (es) 2015-09-25
JP2015532916A (ja) 2015-11-16
JP6186438B2 (ja) 2017-08-23
US20140094450A1 (en) 2014-04-03
AU2013320323A1 (en) 2015-04-16
SI2897939T1 (sl) 2017-05-31
HRP20170628T1 (hr) 2017-06-30
PT2897939T (pt) 2017-05-04
CN104640846A (zh) 2015-05-20
EP2897939B1 (en) 2017-02-01
SG11201501051UA (en) 2015-03-30
KR20150058284A (ko) 2015-05-28
LT2897939T (lt) 2017-05-10
ES2623528T3 (es) 2017-07-11
WO2014044738A1 (en) 2014-03-27
BR112015005972A2 (pt) 2017-07-04
EP2897939A1 (en) 2015-07-29
CA2885272A1 (en) 2014-03-27
US9156796B2 (en) 2015-10-13
IL237212A (en) 2016-10-31
AU2013320323B2 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
DK2897939T3 (da) Benzoimidazolcarboxylsyreamidderivater til behandling af metaboliske eller kardiovaskulære sygdomme
EP2582667B1 (de) Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
EP2771340B1 (en) 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8648038B2 (en) (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2590930B1 (de) Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
MX2013000073A (es) Acidos hidroxifenilhexinoicos ariloxialquileno - sustituidos, procedimiento para su preparacion y su uso como medicamento.
US8846712B2 (en) 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9133181B2 (en) Substituted 6-(4-hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
EP2567959B1 (en) 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2013060370A (ja) キナーゼ阻害剤としての６−（４−ヒドロキシ−フェニル）−３−スチリル−１Ｈ−ピラゾロ［３，４−ｂ］ピリジン−４−カルボン酸アミド誘導体
DE102010015123A1 (de) Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung